1. Home
  2. CASI vs AIXI Comparison

CASI vs AIXI Comparison

Compare CASI & AIXI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CASI
  • AIXI
  • Stock Information
  • Founded
  • CASI 1991
  • AIXI 2001
  • Country
  • CASI China
  • AIXI China
  • Employees
  • CASI N/A
  • AIXI N/A
  • Industry
  • CASI Biotechnology: Pharmaceutical Preparations
  • AIXI Computer Software: Prepackaged Software
  • Sector
  • CASI Health Care
  • AIXI Technology
  • Exchange
  • CASI Nasdaq
  • AIXI Nasdaq
  • Market Cap
  • CASI 29.7M
  • AIXI 35.4M
  • IPO Year
  • CASI 1996
  • AIXI 2023
  • Fundamental
  • Price
  • CASI $1.89
  • AIXI $3.10
  • Analyst Decision
  • CASI Strong Buy
  • AIXI
  • Analyst Count
  • CASI 1
  • AIXI 0
  • Target Price
  • CASI $4.00
  • AIXI N/A
  • AVG Volume (30 Days)
  • CASI 7.1K
  • AIXI 177.3K
  • Earning Date
  • CASI 05-16-2025
  • AIXI 05-15-2025
  • Dividend Yield
  • CASI N/A
  • AIXI N/A
  • EPS Growth
  • CASI N/A
  • AIXI N/A
  • EPS
  • CASI N/A
  • AIXI N/A
  • Revenue
  • CASI $31,368,000.00
  • AIXI $70,314,315.00
  • Revenue This Year
  • CASI N/A
  • AIXI $26.84
  • Revenue Next Year
  • CASI N/A
  • AIXI N/A
  • P/E Ratio
  • CASI N/A
  • AIXI N/A
  • Revenue Growth
  • CASI 8.39
  • AIXI 18.84
  • 52 Week Low
  • CASI $1.64
  • AIXI $2.06
  • 52 Week High
  • CASI $7.67
  • AIXI $8.87
  • Technical
  • Relative Strength Index (RSI)
  • CASI 47.25
  • AIXI 44.89
  • Support Level
  • CASI $1.77
  • AIXI $3.05
  • Resistance Level
  • CASI $1.98
  • AIXI $3.78
  • Average True Range (ATR)
  • CASI 0.10
  • AIXI 0.40
  • MACD
  • CASI 0.01
  • AIXI -0.05
  • Stochastic Oscillator
  • CASI 54.55
  • AIXI 32.44

About CASI CASI Pharmaceuticals Inc.

CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA.

About AIXI XIAO-I Corporation

XIAO-I Corp is an AI industrialization company focusing on the AI Cognitive Intelligence platform. The platform combines six core technologies including Natural Language Processing, Speech Processing, Computer Vision, Machine Learning, Affective Computing, Data Intelligence, and Hyper- automation. Based on the platform, The company developed products and solutions in the fields of Al+ Contact Center, Al+ Finance, Al+ City Public Service, Al+ Architecture, Al+ Metaverse, Al+ Manufacturing, and Al+ Healthcare. It generates revenue from the sale of software products and services, M&S services, and the sale of cloud platform products.

Share on Social Networks: